ROSSINI, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.402
NA - Nord America 2.234
EU - Europa 1.197
SA - Sud America 207
AF - Africa 48
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.118
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.168
CN - Cina 810
SG - Singapore 681
RU - Federazione Russa 523
IT - Italia 395
KR - Corea 224
BD - Bangladesh 183
HK - Hong Kong 172
BR - Brasile 156
VN - Vietnam 150
IN - India 56
FR - Francia 51
FI - Finlandia 50
GB - Regno Unito 35
CA - Canada 33
PL - Polonia 33
JP - Giappone 30
DE - Germania 28
AU - Australia 27
AR - Argentina 19
ID - Indonesia 19
MX - Messico 16
NG - Nigeria 16
IE - Irlanda 14
AE - Emirati Arabi Uniti 13
SE - Svezia 12
IQ - Iraq 11
NL - Olanda 11
EC - Ecuador 10
JO - Giordania 10
PK - Pakistan 9
BJ - Benin 8
CO - Colombia 8
ES - Italia 8
UA - Ucraina 8
SA - Arabia Saudita 7
ZA - Sudafrica 7
CZ - Repubblica Ceca 6
PT - Portogallo 6
PH - Filippine 5
UZ - Uzbekistan 5
CR - Costa Rica 4
EG - Egitto 4
KE - Kenya 4
BH - Bahrain 3
CL - Cile 3
GR - Grecia 3
HN - Honduras 3
JM - Giamaica 3
MA - Marocco 3
PE - Perù 3
PY - Paraguay 3
TR - Turchia 3
VE - Venezuela 3
AT - Austria 2
AZ - Azerbaigian 2
DO - Repubblica Dominicana 2
IL - Israele 2
KW - Kuwait 2
LT - Lituania 2
MD - Moldavia 2
TH - Thailandia 2
AL - Albania 1
BE - Belgio 1
BO - Bolivia 1
BY - Bielorussia 1
BZ - Belize 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CW - ???statistics.table.value.countryCode.CW??? 1
DZ - Algeria 1
EE - Estonia 1
GH - Ghana 1
LK - Sri Lanka 1
LV - Lettonia 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
PA - Panama 1
PR - Porto Rico 1
QA - Qatar 1
RO - Romania 1
RS - Serbia 1
SV - El Salvador 1
TG - Togo 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.118
Salva come PNG Salva come JPEG
Città #
Santa Clara 896
Singapore 548
Hefei 328
Ashburn 275
Seoul 224
San Jose 208
Hong Kong 167
Beijing 77
Milan 62
Los Angeles 54
Ho Chi Minh City 51
Hanoi 41
New York 41
Lauterbourg 40
Council Bluffs 38
Rome 37
Kent 35
Helsinki 34
Buffalo 33
The Dalles 33
Warsaw 30
Melbourne 27
Florence 25
London 23
Mumbai 23
Bengaluru 22
Moscow 21
Dallas 18
Tokyo 17
Abuja 15
Shanghai 15
São Paulo 15
Dublin 14
Naples 14
Toronto 14
Arezzo 13
Lappeenranta 13
Tianjin 13
Jakarta 12
Orem 12
Chicago 11
Bologna 10
Cologne 10
Chandler 9
Haiphong 9
Cotonou 8
Turin 8
Baghdad 7
Boston 7
Brooklyn 7
North Charleston 7
Rio de Janeiro 7
Seattle 7
Boardman 6
Da Nang 6
Elk Grove Village 6
Las Vegas 6
Mexico City 6
Munich 6
Salvador 6
San Francisco 6
Dhaka 5
Fairfield 5
Frankfurt am Main 5
Genoa 5
Houston 5
Lisbon 5
Montreal 5
Mosier 5
Pisa 5
Poplar 5
Salt Lake City 5
Shenzhen 5
Yubileyny 5
Amman 4
Bari 4
Cagliari 4
Curitiba 4
Figino 4
Modena 4
Padua 4
Palermo 4
Phoenix 4
Podivín 4
San Rafael 4
Stockholm 4
Tashkent 4
West Jordan 4
Atlanta 3
Bismarck 3
Cairo 3
Cambridge 3
Can Tho 3
Chengdu 3
Chennai 3
Columbus 3
Gradignan 3
Guangzhou 3
Guayaquil 3
Indpls 3
Totale 3.890
Salva come PNG Salva come JPEG
Nome #
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 251
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 235
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications 181
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer 171
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 169
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by GONO Foundation 168
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study 168
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer 167
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 161
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 159
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO 157
Clinical nutrition in surgical oncology: Young AIOM-AIRO-SICO multidisciplinary national survey on behalf of NutriOnc research group 153
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study 152
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials 152
KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration 150
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV 148
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature 144
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 144
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: Lessons from the AtezoT RIBE study 141
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO 138
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer The Phase 2 Single-Arm Clinical CAVE Trial 135
EGFR Amplification in Metastatic Colorectal Cancer 135
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer 133
ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer 129
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials 127
Vessel-Guided Mesohepatectomy for Liver Partition and Staged Major Parenchyma-Sparing Hepatectomies with Super-Selective Portal Vein Embolization or Enhanced ALPPS to Achieve R0 Resection for Colorectal Liver Metastases at the Hepatocaval Confluence 125
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies 124
KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population 124
Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm 116
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study 113
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 112
KDR genetic predictor of toxicities induced by sorafenib and regorafenib 111
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter? 109
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 105
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies 101
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 100
Network meta-analysis of adjuvant chemotherapy in biliary tract cancers: Setting the scene for new randomized evidence 93
The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm? 90
Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: Results from the MAVERIC Phase II Trial (1499 WORDS MAIN TEXT) 88
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset 83
Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer 82
Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO 78
Individual patient data meta-analysis of folfoxiri plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer 66
A Snapshot from the Italian Clinical Practice Regarding Efficacy and Utility Rate of Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: The RealBLADDER Study 58
Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine–nab-paclitaxel failure: a propensity score-matched analysis 49
Beneath the surface of colorectal cancer: Unmasking the evolving nature of (Neo)RAS 47
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study 47
Radiomics-based prediction of microsatellite instability in colorectal cancer: a non-invasive approach to treatment stratification 45
Immune checkpoint inhibitors in the first-line treatment of esophageal squamous cell carcinoma: Minireview for a big shift 45
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO 39
Prediction of Microsatellite Instability in Colorectal Cancer Using Two Internally Validated Radiomic Models 37
Microbiome dysbiosis and KRAS-driven tumorigenesis in pancreatic cancer: implications for immune checkpoint inhibitors efficacy 23
Navigating Disappearing Liver Metastases in Colorectal Cancer: A Review of Surgical and Non-Surgical Approaches 22
Totale 6.200
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.649
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.649
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20227 0 0 0 1 0 0 0 1 0 1 2 2
2022/202360 1 8 1 2 2 10 10 5 12 0 6 3
2023/2024144 1 5 4 10 4 10 9 31 2 54 9 5
2024/20252.111 75 200 100 206 658 370 77 45 77 41 108 154
2025/20263.629 282 447 514 302 344 94 329 210 281 202 288 336
2026/2027206 206 0 0 0 0 0 0 0 0 0 0 0
Totale 6.200